Atlas Trials

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Clinical trial NCT03559387 · TERMINATED

Trial details

NCT number
NCT03559387
Sponsor
Prolong Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Chemotherapy-induced Neutropenia
Start date
2017-08-03
Primary completion
2018-04-18
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.